# Pharmaceutical Competitive Landscape Analysis Guide

## Overview

This comprehensive guide provides systematic instructions for conducting competitive landscape analyses in pharmaceutical and biotechnology sectors, focusing on specific targets, mechanisms of action (MoA), or therapeutic indications. The guide incorporates proven data organization methodologies from radiopharmaceutical, VEGFR inhibitor, and PARP inhibitor competitive analyses.

## Section 1: Analysis for Specific Target or MoA

### 1. Literature Review Search Strategy

**Search Parameters:**

- Primary search: "[Target Name]" AND "Review"
- Time frame: Last 3-5 years only
- Focus: Review articles exclusively (exclude primary research papers)

**Exclusion Criteria:**

- Reviews authored by researchers from Iranian or Indian academic institutions or medical centers
- Primary research papers (due to potential retraction risks at this stage)

### 2. Competitive Landscape Development

**Essential Data Points:**

- **INN** (International Nonproprietary Name)
- **Brand names/Development codes** (multiple possible due to licensing - search all variants)
- **Developer(s)/Company(ies)**
- **Target specificity** (verify detailed subtypes)
- **Indications** (approved and in development)
- **Combination therapies** (specify combination drugs by indication)
- **Industry collaborators** (by indication)
- **Dosing and regimen**
- **Latest development stage** (by indication)
- **Patent information**

**Class-Specific Factors for Differentiation Analysis:**

- Efficacy parameters
- Safety profile and toxicity data
- Production specifications (host systems, manufacturing processes)
- Formulation details
- Dosing and administration regimen

### 3. Reference Sources

**Approved Drugs:**

- FDA Database: [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)
- EMA Database: [https://www.ema.europa.eu/en/medicines](https://www.ema.europa.eu/en/medicines)

**Clinical Development:**

- ClinicalTrials.gov
- WHO International Clinical Trials Registry: trialsearch.who.int

**Patent Research:**

- KIPRIS (Korea): [https://www.kipris.or.kr/khome/main.do](https://www.kipris.or.kr/khome/main.do)
    - Search parameters:
        - Applicant: Development companies
        - Inventors: Executive team, Scientific Advisory Board (SAB), Technical/Science executives
        - University Technology Transfer Offices (TTOs) associated with SAB members
        - Claims analysis

**Additional Sources:**

- Company websites
- Google search (beyond news articles)
- Maximum 20 pages of Google results (extend to 40 pages if initial results are limited)

## Section 2: Analysis for Specific Therapeutic Indication

### 1. Initial Literature Review

(Follow same search strategy as Section 1.1)

### 2. Approved Therapeutics Competitive Landscape

**Priority Focus:** Begin with FDA/EMA approved drugs and therapies

**Data Collection:** (Follow same essential data points and class-specific factors as Section 1.2)

### 3. Pipeline Therapeutics Competitive Landscape

**Development Stage Analysis:**

- Include all clinical development stages
- Track both monotherapy and combination approaches
- Monitor licensing and collaboration changes

**Special Considerations for Combination Therapies:**

- When combination includes approved drugs: Cross-reference with FDA/EMA databases
- Verify all partner drug information
- Document indication-specific combinations

### 4. Comprehensive Source Verification

(Use all reference sources listed in Section 1.3)

## Section 3: Systematic Data Organization Framework

### 3.1 Data Collection Template

**Core Data Fields (Required for all analyses):**

1. **Product Information:**
   - Product Name (INN/Brand/Development Code)
   - Company/Developer
   - Country of Origin
   - Listed Status (Public/Private)

2. **Technical Specifications:**
   - Target (Primary/Secondary)
   - Platform Technology (Antibody, Peptide, Small molecule, etc.)
   - Mechanism of Action (MoA)
   - Molecular Structure/Class

3. **Development Status:**
   - Current Stage (Discovery, Preclinical, Phase I-III, Approved, Commercial)
   - Indication (Primary/Secondary)
   - Combination Status (Monotherapy/Combination)
   - Partner Companies

4. **Regulatory & Commercial:**
   - Approval Status by Region
   - Patent Expiration Timeline
   - Licensing Agreements
   - Market Access Status

### 3.2 Target-Specific Data Collection Examples

**For Radiopharmaceuticals (134 companies analyzed):**
- Isotope Type (225-Ac, 177-Lu, 131-I, 90-Yt)
- Platform (Mini-protein, Peptide, Antibody)
- Target Specification
- Development Stage Distribution
- Geographic Focus
- Partnership Networks

**For VEGFR Inhibitors (86 products analyzed):**
- Target Selectivity (VEGFR-1,2,3 combinations)
- Indication Detail (Specific cancer types)
- Combination Partners
- Stage Distribution (Approved to Phase 1)
- Market Positioning

**For PARP Inhibitors (118 products analyzed):**
- PARP Selectivity (PARP1/2, PARP1/2/3)
- Indication Focus (Ovarian, Breast, Prostate cancer)
- Biomarker Requirements
- Combination Strategies
- Resistance Mechanisms

### 3.3 Partnership Analysis Framework

**Partner Categorization:**
1. **Licensing Partners:** Technology in/out agreements
2. **Co-development Partners:** Joint development programs
3. **Commercial Partners:** Distribution and marketing
4. **Platform Partners:** Technology platform providers

**Partnership Evaluation Matrix:**
| Company | Technology Class | Competing Product | Combination Potential | Development Status | Collaboration Interest | Notes |
|---------|------------------|-------------------|----------------------|-------------------|----------------------|-------|
| [Company] | [Tech Platform] | [Product Name] | [Combination Drug] | [Phase X] | [High/Medium/Low] | [Special Notes] |

## Section 4: Advanced Analysis Methods

### 4.1 Keyword-Based Classification System

**Therapeutic Areas:**
- Cholangiocarcinoma
- Hepatocellular Carcinoma
- Non-Small Cell Lung Cancer (NSCLC)
- [Additional indications as needed]

**Target/Mechanism Keywords:**
- PARP (PARP1, PARP2, PARP1/2, PARP1/2/3)
- VEGFR (VEGFR-1, VEGFR-2, VEGFR-3, multi-target)
- RBM39
- Synthetic Lethality
- [Additional targets as needed]

**Technology Platform Keywords:**
- Monoclonal Antibody
- Peptide Conjugate
- Small Molecule
- Radiopharmaceutical
- Cell Therapy
- Gene Therapy

### 4.2 Competitive Intelligence Data Matrix

**Standard Analysis Format:**
```
| Field | Description | Data Source | Update Frequency |
|-------|-------------|-------------|-----------------|
| Product Name | INN/Brand/Code | FDA/EMA/Company | Monthly |
| Developer | Primary Company | Company Reports | Quarterly |
| Target | Molecular Target | Literature/Patents | Semi-annually |
| Stage | Development Phase | ClinicalTrials.gov | Monthly |
| Indication | Therapeutic Use | Regulatory Filings | Quarterly |
| Combination | Partner Drugs | Clinical Protocols | Monthly |
| Partners | Collaboration | Press Releases | Real-time |
| Patents | IP Status | Patent Databases | Quarterly |
```

### 4.3 Market Gap Analysis

**Unmet Medical Needs Identification:**
1. Efficacy Limitations in Current Therapies
2. Safety/Tolerability Issues
3. Resistance Development
4. Patient Access Barriers
5. Quality of Life Factors

**Competitive Positioning Analysis:**
- First-in-class vs. Best-in-class opportunities
- Combination therapy potential
- Patient population segmentation
- Geographic market variations

## Section 5: Partnership Strategy Development

### 5.1 Partner Candidate Identification

**Strategic Partner Categories:**

1. **Global Big Pharma:**
   - Established market access
   - Regulatory expertise
   - Commercial infrastructure
   - Financial resources

2. **Regional Specialists:**
   - Local market knowledge
   - Regulatory relationships
   - Distribution networks
   - Cultural understanding

3. **Biotech Innovators:**
   - Complementary technologies
   - Novel combinations
   - Agility and speed
   - Innovation focus

4. **Platform Technology Companies:**
   - Enabling technologies
   - Manufacturing capabilities
   - Specialized expertise
   - Infrastructure access

### 5.2 Partnership Evaluation Criteria

**Technical Fit:**
- Complementary mechanisms
- Synergistic combinations
- Platform compatibility
- Manufacturing synergies

**Strategic Alignment:**
- Therapeutic area focus
- Geographic priorities
- Development timelines
- Commercial objectives

**Commercial Viability:**
- Market potential
- Competitive positioning
- Pricing strategies
- Reimbursement pathways

**Risk Assessment:**
- Technical risks
- Regulatory risks
- Commercial risks
- Partner-specific risks

## Section 6: Continuous Monitoring System

### 6.1 Real-time Intelligence Updates

**Monthly Monitoring:**
- Clinical trial progressions
- Regulatory submissions
- Partnership announcements
- Patent applications/grants

**Quarterly Analysis:**
- Market share evolution
- New market entrants
- Technology trend analysis
- Regulatory environment changes

**Annual Strategic Review:**
- Portfolio repositioning
- Partnership strategy updates
- Investment priority adjustments
- Competitive position reassessment

### 6.2 Data Quality Assurance

**Verification Standards:**
- Primary source preference (FDA/EMA official data)
- Multi-source cross-validation
- Currency requirements (<6 months)
- Reliability assessment (peer-reviewed sources)

**Update Protocols:**
- Automated data feeds where possible
- Manual verification for critical updates
- Version control for historical tracking
- Stakeholder notification systems

## Report Structure Guidelines

### Executive Summary Format

1. Target/MoA or Indication overview
2. Market landscape summary
3. Key competitive advantages/challenges
4. Development pipeline highlights
5. Partnership opportunities and recommendations

### Detailed Analysis Sections

1. **Approved Therapeutics**
    - Comprehensive profiles by product
    - Market performance data
    - Patent expiration timelines
    - Competitive positioning

2. **Clinical Pipeline**
    - Phase III candidates (nearest to market)
    - Phase II programs (mid-stage)
    - Phase I/Preclinical (early stage)
    - Technology platform analysis

3. **Differentiation Analysis**
    - Efficacy comparisons
    - Safety profile distinctions
    - Manufacturing/formulation advantages
    - Dosing convenience factors
    - Patient population targeting

4. **Strategic Insights**
    - Partnership opportunities
    - Market gaps identification
    - Development risks assessment
    - Competitive threats analysis

5. **Partnership Recommendations**
    - Prioritized partner candidates
    - Collaboration models
    - Risk mitigation strategies
    - Implementation timeline

## Quality Control Checklist

- [ ]  All reviews from last 3-5 years reviewed
- [ ]  Excluded papers from restricted sources
- [ ]  All brand names/development codes searched
- [ ]  Patent landscape comprehensive
- [ ]  Clinical trial databases fully searched
- [ ]  Cross-verification completed across sources
- [ ]  Differentiation factors analyzed
- [ ]  All indications covered
- [ ]  Collaboration details verified
- [ ]  Partnership potential assessed
- [ ]  Data matrix completed per template
- [ ]  Update schedule established
- [ ]  Quality assurance protocols implemented

## Usage Instructions

This guide can be used as:

1. A systematic prompt for AI-assisted research
2. A checklist for manual competitive intelligence gathering
3. A template for standardizing competitive landscape reports
4. Training material for new analysts in pharmaceutical competitive intelligence
5. A framework for partnership strategy development
6. A continuous monitoring system blueprint

When using as a prompt, specify:

- The specific target/MoA or indication
- Any additional company or geographic focus
- Desired output format (table, narrative, presentation)
- Priority ranking criteria (e.g., development stage, company size, efficacy)
- Partnership objectives and criteria
- Data update requirements and frequency

## Implementation Notes

This framework has been validated through analyses of:
- 134 radiopharmaceutical companies with 23 data fields
- 86 VEGFR inhibitor products with 13 data fields
- 118 PARP inhibitor products with 13 data fields
- Multiple partnership candidate databases
- Keyword-based classification systems

The methodology ensures comprehensive coverage while maintaining data quality and strategic relevance for pharmaceutical competitive intelligence and partnership development.